eMedinewS Editorial

Health Care 122 Comments

Bromocriptine and type 2 diabetes

Bromocriptine an ergot–derived dopamine agonist has been used for over two decades for the treatment of hyperprolactinemia and Parkinson’s disease. A quick–release formulation of bromocriptine has been approved by the US FDA for the treatment of type 2 diabetes mellitus. In short–term clinical trials in patients with type 2 diabetes mellitus, quick–release bromocriptine (up to 4.8 mg daily) as monotherapy or as adjunctive therapy to sulfonylureas was minimally effective in reducing A1c compared with placebo. Common side effects include nausea, vomiting, dizziness, and headache. The mechanism of action in reducing blood sugar is unknown.

eMedinewS Comments: Given its modest glucose–lowering effect, very frequent GI side effects, and the availability of more effective drugs, there is no recommendation to use bromocriptine for the treatment of type 2 diabetes.

Dr KK Aggarwal
Editor in Chief